Tango Therapeutics, Inc. (TNGX) Upgraded to Buy at Jefferies

Market Context

Tango Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $30.26 with a market capitalization of $1.0B. The stock has gained 447.4% over the past 52 weeks.

Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Jefferies's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Tango Therapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Jun 26, 2026	Jefferies	Buy	N/A
Jun 11, 2026	Canaccord Genuity	Buy	N/A
Jun 09, 2026	HC Wainwright & Co.	Buy	N/A
Jun 09, 2026	Canaccord Genuity	Buy	N/A
Jun 08, 2026	Leerink Partners	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View TNGX Stock Page